Lapsed Aug 8, 2025 on the fee record · Medium confidence
20-year base term ends Sep 6, 2033
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 9,346,880, US 9,382,317), so the cap could be lower.
Second maintenance fee unpaid; grace period ended.
Sep 6, 2013
Aug 8, 2025
Aug 8, 2017
Sep 6, 2033
Its term would have run to Sep 6, 2033: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 6, 2013, when application 14/020,733, the earliest non-provisional in its chain, was filed (this one was filed Oct 9, 2015) | Sep 6, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,387,884, US 9,340,611, US 9,346,880, US 9,382,317) | resolves to Sep 6, 2033, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Aug 8, 2025 | High confidence |
| Computed term end | The steps above, in order | Aug 8, 2025 | Medium confidence |
This family
| Application 14/020,733 | Abandoned not computed | not computed |
| US 9,340,611 | Lapsed on the fee record May 2024 | May 2024 |
| US 9,340,612 | Lapsed on the fee record May 2024 | May 2024 |
| US 9,782,479 | Lapsed on the fee record Oct 2025 | Oct 2025 |
| US 9,346,880 | Lapsed on the fee record May 2024 | May 2024 |
| US 9,382,317 | Lapsed on the fee record Jul 2024 | Jul 2024 |
| US 9,724,414 | this patent Aug 2025 | Aug 2025 |
| US 9,808,525 | Lapsed on the fee record Nov 2025 | Nov 2025 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 7, 2016 Reel 37428, frame 498 | Manning, Mark; Payne, Robert | Coherus Biosciences, Inc. | Assignment of Assignor's Interest |
| Jan 7, 2019 Reel 48021, frame 975 | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | HCR Collateral Management, LLC, as Administrative Agent | Security Interest |
| Jan 11, 2022 Reel 58692, frame 665 | HCR Collateral Management, LLC | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Jan 11, 2022 reel/frame not recorded | HCR Collateral Management, LLC | Coherus Biosciences, Inc. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Jan 11, 2022 reel/frame not recorded | HCR Collateral Management, LLC | Coherus Intermediate Corp. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Jan 11, 2022 reel/frame not recorded | HCR Collateral Management, LLC | Intekrin Therapeutics Inc. | Release of Notice of Grant of Security Interest in Patents at Reel/Frame No. 048021/0975 |
| Mar 18, 2022 Reel 59436, frame 55 | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | Biopharma Credit PLC | Security Interest |
| May 8, 2024 Reel 67348, frame 160 | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc.; Surface Oncology, LLC; Coherus Oncology Supportive Care LLC | Ankura Trust Company, LLC | Security Interest |
| May 9, 2024 Reel 67378, frame 256 | Biopharma Credit PLC, as Collateral Agent | Coherus Biosciences, Inc.; Coherus Intermediate Corp.; Intekrin Therapeutics Inc. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| May 9, 2024 reel/frame not recorded | Biopharma Credit PLC, as Collateral Agent | Coherus Biosciences, Inc. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| May 9, 2024 reel/frame not recorded | Biopharma Credit PLC, as Collateral Agent | Coherus Intermediate Corp. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| May 9, 2024 reel/frame not recorded | Biopharma Credit PLC, as Collateral Agent | Intekrin Therapeutics Inc. | Termination and Release of Security Interest in Intellectual Property at Reel/Frame No. 59436/0055 |
| Oct 31, 2024 Reel 69084, frame 884 | Coherus Biosciences, Inc. | Hong Kong King-Friend Industrial Company Ltd. | Assignment of Assignor's Interest |
| Aug 14, 2026 Reel 76509, frame 590 | Ankura Trust Company, LLC, as Collateral Agent | Coherus Oncology, Inc. (F/K/A Coherus Biosciences, Inc.); Coherus Intermediate Corp.; Intekrin Therapeutics Inc.; Surface Oncology, LLC; Coherus Oncology Supportive Care LLC | Release of Security Interest in Intellectual Property at Reel/Frame No. 67348/0160 |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 10,387,884, US 9,340,611, US 9,346,880, US 9,382,317, ends no earlier than this term, so it caps nothing.